LENG9 Gene as Potential Drug Target Or Biomarker for Various Diseases

Target Name: LENG9

NCBI ID: G94059

LENG9

LENG9 Gene as Potential Drug Target Or Biomarker for Various Diseases

LENG9 (LENG9 variant 1) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LENG9 is a gene that encodes a protein known as longenylated RNA binding protein 9, which is involved in the regulation of RNA metabolism.

The LENG9 gene has been shown to be mutated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These mutations have been associated with the development of diseases that are characterized by the accumulation of misfolded RNA, such as those leading to neurodegeneration diseases (including dementia, Parkinson's disease and Alzheimer's disease), cancer, and autoimmune diseases.

In addition, the LENG9 gene has also been shown to be involved in regulating the expression of RNA-binding protein 9. RNA-binding protein is an important protein that can bind to RNA molecules to regulate gene expression. Variations in the LENG9 gene may affect the expression level of RNA-binding protein 9, thereby affecting intracellular RNA metabolism. These changes may lead to changes in the RNA molecular structure, leading to protein dysfunction and ultimately the formation of disease.

Variations in the LENG9 gene are also associated with some neurodegenerative diseases. For example, variations in the LENG9 gene have been found in the brains of Alzheimer's disease patients. These mutated genes may affect RNA metabolism in the brain, leading to nerve cell death and the development of neurodegenerative diseases.

In addition, mutations in the LENG9 gene have been associated with cancer. Studies have shown that variations in the LENG9 gene are associated with the occurrence of various cancers, including liver cancer, breast cancer, and lung cancer. These mutated genes may affect RNA metabolism, leading to the growth and spread of tumor cells.

Variations in the LENG9 gene have also been associated with immune diseases. Studies have shown that variations in the LENG9 gene are associated with the development of a variety of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and scleroderma. These mutated genes may affect RNA metabolism, leading to immune cell dysfunction and ultimately the development of autoimmune diseases.

Therefore, variations in the LENG9 gene are a promising drug target or biomarker that can be used to treat various diseases. Studying the variation of the LENG9 gene and its relationship with diseases will help develop new treatments and diagnostic tools and provide better methods for the treatment and prevention of diseases.

Protein Name: Leukocyte Receptor Cluster Member 9

The "LENG9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LENG9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets